Products

No products yet

Press Releases

Relevance
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated AML and IDH1-mutated CCA
Servier Pharmaceuticals
Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
Servier Pharmaceuticals
Servier Bolsters Position as the Leader in Mutant IDH Inhibition with Positive New IDH1-Mutated Acute Myeloid Leukemia Data at ASCO
Servier Pharmaceuticals

Show Specials

No show specials yet

Videos

No videos yet

Browse Categories

Press Releases
4 Items
Products
0 Items
Show Specials
0 Items